Clinical Trials Logo
  1. Home
  2. Extranodal NK/T-cell Lymphoma
  3. NCT04554511
  4. Details
NCT04554511 Clinical Trial

Prognostic Nomogram of Extranodal NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma Clinical Trial

Official title:
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma: A Multi-center Retrospective Study

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04554511
Other study ID # ENKTL-2020
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 28, 2020
Est. completion date January 1, 2024

Study information
Verified date June 2023
Source Sun Yat-sen University
Contact Hua Wang
Phone +862087342462
Email wanghua@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to evaluate prognostic factors for overall survival and explore risk progression-free survival in ENKTL, and establish a prognostic predictive nomogram for ENKTL patients.

Description:

This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL between January 1, 2000 and August 31, 2020; (2) Patients older than 18 years. The pathology of initial diagnosis was reviewed by designated pathologists.

Recruitment information / eligibility
Status Recruiting
Enrollment 1000
Est. completion date January 1, 2024
Est. primary completion date January 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients newly diagnosed with ENKTL - Patients diagnosed between January 1, 2000 and August 31, 2020 - Patients older than 18 years Exclusion Criteria: - Patients who did not have complete clinical information or immunohistochemistry, or who were lost follow-up immediately after treatment.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)
Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Overall survival Time between the date of diagnosis and any kinds of death 5 year
Secondary Progression-free survival Time between the date of diagnosis and any kinds of death or relapse/progression 5 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Recruiting NCT04917250 - GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma Phase 2
Not yet recruiting NCT04337593 - Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL Phase 2
Active, not recruiting NCT04414163 - A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type Phase 2
Not yet recruiting NCT05700448 - Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Phase 3
Active, not recruiting NCT03246750 - B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT03598959 - Tofacitinib Combined With Chidamide in R/R ENKTCL Phase 2
Recruiting NCT00725231 - Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Phase 3
Recruiting NCT03671850 - VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients Phase 2
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2
Recruiting NCT04279379 - Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma Phase 2
No longer available NCT05131438 - An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)